Publications by authors named "Fereguetti T"
Background: Systemic sporotrichosis occurs when organs, other than subcutaneous tissues and lymph nodes, are infected. Interestingly, systemic sporotrichosis in apparently immunocompetent individuals is increasing in Brazil, but data on clinical manifestations and risk factors are scarce. Most of the existing data on such condition relate to people living with HIV.
View Article and Find Full Text PDFSecondary fungal infections are frequently observed in COVID-19 patients. However, the occurrence of candiduria in these patients and its risk factors are underexplored. We evaluated the risk factors of candiduria in COVID-19 patients, including inflammatory mediators that could be used as prognostic markers.
View Article and Find Full Text PDFPotential and limitations of machine meta-learning (ensemble) methods for predicting COVID-19 mortality in a large inhospital Brazilian dataset.
Sci Rep
March 2023
The majority of early prediction scores and methods to predict COVID-19 mortality are bound by methodological flaws and technological limitations (e.g., the use of a single prediction model).
View Article and Find Full Text PDFThe COVID-19 pandemic caused unprecedented pressure over health care systems worldwide. Hospital-level data that may influence the prognosis in COVID-19 patients still needs to be better investigated. Therefore, this study analyzed regional socioeconomic, hospital, and intensive care units (ICU) characteristics associated with in-hospital mortality in COVID-19 patients admitted to Brazilian institutions.
View Article and Find Full Text PDFSecondary infections are one of the complications in COVID-19 patients. We aimed to analyze the antimicrobial prescriptions and their influence on drug resistance in fungi and bacteria isolated from severely ill COVID-19 patients. Seventy-nine severely ill COVID-19 hospitalized patients with secondary bacterial or fungal infections were included.
View Article and Find Full Text PDFPrevious studies that assessed risk factors for venous thromboembolism (VTE) in COVID-19 patients have shown inconsistent results. Our aim was to investigate VTE predictors by both logistic regression (LR) and machine learning (ML) approaches, due to their potential complementarity. This cohort study of a large Brazilian COVID-19 Registry included 4120 COVID-19 adult patients from 16 hospitals.
View Article and Find Full Text PDFChagas disease (CD) continues to be a major public health burden in Latina America. Information on the interplay between COVID-19 and CD is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients.
View Article and Find Full Text PDFArticle Synopsis
- Many existing mortality risk scores for COVID-19 patients have high bias, prompting the need for a more reliable evaluation tool.
- A new prediction model was developed using data from nearly 4,000 COVID-19 patients, identifying seven key variables that indicate in-hospital mortality risk.
- This model showed strong accuracy in predicting outcomes and is accessible through an online calculator for healthcare professionals.*
Article Synopsis
- SARS-CoV-2 can lead to secondary infections, significantly increasing mortality risk among hospitalized COVID-19 patients, with a study showing a 50.47% death rate in severely ill cases.
- Coinfected patients, particularly with bacterial and fungal pathogens, had a substantially higher odds of death (up to 13.45 times more likely), especially if they had existing comorbidities like cardiovascular disease, diabetes, or obesity.
- Early identification and diagnosis of these coinfections are crucial for improving patient outcomes and reducing mortality rates.
Introduction: There are few drugs with proven efficacy in cutaneous leishmaniasis (CL), and pentavalent antimonial derivatives are still the main first-line therapeutic agents worldwide, despite their recognized high toxicities. Randomized controlled clinical trials assessing the efficacy and safety of new therapeutic modalities are of high priority, and the definition of the design of such trials raises debate about the use of placebo as a comparator. To support the use of placebo as a comparator, two main points need to be addressed: 1--the cure rate without any therapeutic intervention and 2--the damage caused by CL and its impact on patients.
View Article and Find Full Text PDFObjective: We conducted a systematic literature review with indirect comparison of studies evaluating therapeutic efficacy and toxicity associated to visceral leishmaniasis (VL) therapy among HIV infected individuals.
Main Outcome Measurements: The outcomes of interest were clinical and parasitological cure, mortality, and adverse events.
Methods: PRISMA guidelines for systematic reviews and Cochrane manual were followed.